To find a doctor, call 800-667-5356 or click below:

Find a Doctor

Request an Appointment

Home
About
BIDMC
Centers and
Departments
Patient and Visitor
Information
Quality and
Safety
iHealth
Medical
Education
Research
Give to
BIDMC
left banner
right banner
Smaller Larger

Select Publications

Original Publications: 2005-2009


  1. Ciccocioppo R, Sabatino AD, Bauer M, Riccia DN, Bizzini F, Biagi F, Cifone MG, Corazza GR, Schuppan D. Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest. 2005;85:397-407.
  2. Osterreicher CH, Datz C, Stickel F, Hellerbrand C, Penz M, Hofer H, Wrba F, Penner E, Schuppan D, Ferenci P. Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. J Hepatol 2005;42:914-9.
  3. Pavel ME, Hassler G, Baum U, Hahn EG, Lohmann T, Schuppan D. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol 2005;62:434-43.
  4. von Moers A, Zwirner A, Reinhold A, Bruckmann O, van Landeghem F, Stoltenburg-Didinger G, Schuppan D, Herbst H, Schuelke M. Increased mRNA expression of tissue inhibitors of metalloproteinase-1 and -2 in Duchenne muscular dystrophy. Acta Neuropathol 2005; 109:285-93.
  5. Ocker M, Alajati A, Ganslmayer M, Zopf S, Luders M, Neureiter D, Hahn EG, Schuppan D, Herold C. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 2005;131:385-94.
  6. Graepler F, Verbeek B, Graeter T, Smirnow I, Kong HL, Schuppan D, Bauer M, Vonthein R, Gregor M, Lauer UM. Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology 2005;41:879-86.
  7. Dan Z, Popov Y, Patsenker E, Preimel D, Liu C, Wang XD, Seitz HK, Schuppan D, Stickel F. Hepatotoxicity of alcohol-induced polar retinol metabolites involves apoptosis via loss of mitochondrial membrane potential. FASEB J 2005;19:845-7.
  8. Sutter AP, Maaser K, Hopfner M, Huether A, Schuppan D, Scherubl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005;43:808-16.
  9. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 -/- (Abcb4) mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 2005;43:1045-54.
  10. Schulze-Krebs A, Preimel D, Popov Y, Bartenschlager R, Lohmann V, Pinzani M, Schuppan D. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005;129:246-58.
  11. Osterreicher CH, Datz C, Stickel F, Hellerbrand C, Penz M, Hofer H, Wrba F, Penner E, Schuppan D, Ferenci P. TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine 2005;31:142-8.
  12. Lebensztejn DM, Sobaniec-Łotowska ME, Bauer M, Kaczmarski M, Voelker M, Schuppan D. Serum fibrosis markers as predictors of an antifibrotic effect of interferon alpha in children with chronic hepatitis B. Eur J Gastroenterol Hepatol 2005;17:843-848.
  13. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut 2005;54:1298-308.
  14. Li ZD, Bork JP, Krueger B, Patsenker E, Schulze-Krebs A, Hahn EG, Schuppan D. VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 2005;334:1049-60.
  15. Huether A, Hopfner M, Sutter AP, Schuppan D, Scherubl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005.;43:661-9.
  16. Yedibela S, Schuppan D, Muller V, Schellerer V, Tannapfel A, Hohenberger W, Meyer T. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Liver Int 2005;25:717-22.
  17. Reis RC, Schuppan D, Barreto AC, Bauer M, Bork JP, Hassler G, Coelho-Sampaio T. Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans. Biochem Biophys. Res Commun 2005.333:976-83.
  18. Dieterich D, Esslinger B, Trapp D, Hahn E, Huff T, Seilmeier W, Wieser H, Schuppan D. Crosslinking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease, Gut 2005;55:478-84.
  19. Stickel F, Osterreicher CH, Datz C, Ferenci P, Wolfel M, Norgauer W, Kraus MR, Wrba F, Hellerbrand C, Schuppan D. Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med 2005;165:1835-40.
  20. Ruehl M, Erben U, Schuppan D, Wagner C, Zeller A, Freise C, Al-Hasani H, Loesekann M, Notter M, Wittig BM, Zeitz M, Dieterich W, Somasundaram R. The elongated first fibronectin type lll domain of collagen XIV is an inducer of quiescence and differentiation in fibroblasts and preadipocytes. J Biol Chem 2005;280:38537-43.
  21. Benten D, Kumaran V, Joseph B, Schattenberg J, Popov Y, Schuppan D, Gupta S. Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat. Hepatology 2005;42:1072-81.
  22. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005;70:1568-78.
  23. Ganslmayer M, Ocker M, Zopf S, Schuppan D, Hahn EG, Herold C. Hepatocellular carcinomas do not compromise quantitative tests of liver function. Hepatogastroenterology 2005;52:881-4.
  24. Homann N, Stickel F, Konig IR, Jacobs A, Junghanns K, Benesova M, Schuppan D, Himsel S, Zuber-Jerger I, Hellerbrand C, Ludwig D, Caselmann WH, Seitz K. Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer 2006;18:1998-2002.
  25. Konturek PC, Bazela K, Kukharskyy V, Bauer M, Hahn EG, Schuppan D. Helicobacter pylori upregulates prion protein expression in gastric mucosa: a possible link to prion disease. World J Gastroenterol 2005;28;11:7651-6.
  26. Pavel ME, Baum U, Hahn EG, Schuppan D, Lohmann T. Efficacy and Tolerability of Pegylated IFN-alpha in Patients with Neuroendocrine Gastroenteropancreatic Carcinomas. J Interferon Cytokine Res 2006;26:8-13.
  27. Lohwasser C, Neureiter D, Weigle B, Kirchner T, Schuppan D. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol 2006;126:291-9.
  28. Pavel ME, Hoppe S, Papadopoulos T, Linder V, Mohr B, Hahn EG, Lohmann T, Schuppan D. Adrenomedullin is a Novel Marker of Tumor Progression in Neuroendocrine Carcinomas. Horm Metab Res 2006;38:112-8.
  29. Joos S, Wildau N, Kohnen R, Szecsenyi J, Schuppan D, Willich SN, Hahn EG, Brinkhaus B. Acupuncture and moxibustion in the treatment of ulcerative colitis - a randomized controlled study Scand J Gastroenterol 2006;41:1056-63.
  30. Schurr R, Stolzel U, Schuppan D, Schwertner C, Steinberg J, Scherubl H. Increased incidence of hepatocellular and intrahepatic cholangiocellular cancer in the Northeast of Germany. Dtsch Med Wochenschr 2006;131:1649-55.
  31. Hansler J, Wissniowski TT, Schuppan D, Witte A, Bernatik T, Hahn EG, Strobel D. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 2006;12:3716-21.
  32. Lebensztejn DM, Sobaniec-Lotowska ME, Kaczmarski M, Voelker M, Schuppan D. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol 2006;12:3338-43.
  33. Jurgensen C, Schuppan D, Neser F, Ernstberger J, Junghans U, Stolzel U. EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc 2006;63:1059-62.
  34. Strnad P, Lienau TC, Tao GZ, Lazzeroni LC, Stickel F, Schuppan D, Omary MB. Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology 2006;43:1354-63.
  35. Metzger MH, Heier M, Maki M, Bravi E, Schneider A, Lowel H, Illig T, Schuppan D, Wichmann HE. Mortality Excess in Individuals with Elevated IgA Anti-Transglutaminase Antibodies: The KORA/MONICA Augsburg Cohort Study 1989-1998. Eur J Epidemiol 2006;21:359-65.
  36. Teubner A, Richter M, Schuppan D, Kostler E, Stolzel U. Hepatitis C, hemochromatosis and porphyria cutanea tarda. Dtsch Med Wochenschr 2006;131:691-5.
  37. Hopfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherubl H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 2006;71:1435-48.
  38. Daum S, Foss HD, Schuppan D, Riecken EO, Zeitz M, Ullrich R. Synthesis of Collagen I in Collagenous Sprue. Clin Gastroenterol Hepatol 2006;4:1232-6.
  39. Huether A, Hopfner M, Sutter AP, Baradari V, Schuppan D, Scherubl H. Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 2006;12:5160-7.
  40. Popov Y, Patsenker E, Bauer M, Schulze-Krebs A, Niedobitek E, Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkB. J Biol Chem 281:15090-8.
  41. Rost D, Welker A, Welker J, Millonig G, Berger I, Autschbach F, Schuppan D, Mueller S. Liver-homing of purified glucose oxidase: A novel in vivo model of physiological hepatic oxidative stress (H(2)O(2)).J Hepatol 2006;46:482-91.
  42. Baradari V, Huether A, Hopfner M, Schuppan D, Scherubl H. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 2006;13:1237-50.
  43. Isbert C, Ritz JP, Roggan A, Schuppan D, Ajubi N, Buhr HJ, Hohenberger W, Germer CT. Laser-induced thermotherapy (LITT) elevates mRNA expression of connective tissue growth factor (CTGF) associated with reduced tumor growth of liver metastases compared to hepatic resection. Lasers Surg Med. 2006;39:42-50.
  44. Koda M, Bauer M, Krebs A, Hahn EG, Schuppan D, Murawaki Y. Endothelin-1 enhances fibrogenic gene expression, but does not promote DNA synthesis or apoptosis in hepatic stellate cells. Comp Hepatol 2006;5:5-13.
  45. Patsenker E, Popov Y, Wiesner M, Goodman SL, Schuppan D. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB induced hepatic stellate cell migration and activation in vitro. J Hepatol 2007;46:878-87.
  46. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 2007;73:1308-17.
  47. Leffler DA, Dennis M, Hyett B, Kelly E, Schuppan D, Kelly CP. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 2007;5:445-50.
  48. Leffler DA, Edwards-George JB, Dennis M, Cook EF, Schuppan D, Kelly CP. A prospective comparative study of five measures of gluten-free diet adherence in adults with coeliac disease.Aliment Pharmacol Ther 2007;26:1227-35.
  49. Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G, Kolb A, Friess H, Schuppan D. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008:48:453-64.
  50. Künzli BM, Nuhn P, Enjyoji K, Banz Y, Smith RN, Csizmadia E, Schuppan D, Berberat PO, Friess H, Robson SC. Disordered Pancreatic Inflammatory Responses and Inhibition of Fibrosis in CD39-Null Mice. Gastroenterology 2008:134:292-305.
  51. Leffler DA, Edwards-George J, Dennis M, Schuppan D, Cook F, Franko DL, Blom-Hoffman J, Kelly CP. Factors that Influence Adherence to a Gluten-Free Diet in Adults with Celiac Disease. Dig Dis Sci 2008;53:1573-81.
  52. Stickel F, Osterreicher CH, Halangk J, Berg T, Homann N, Hellerbrand C, Patsenker E, Schneider V, Kolb A, Friess H, Schuppan D, Puhl G, Seitz HK, Leathart JL, Day CP. No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease. Alcohol Clin Exp Res 2008:32:959-65.
  53. Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D. Inhibition of integrin alphavbeta6 on bile duct epithelial cells blocks tgfbeta activation and retards progression of biliary fibrosis. Gastroenterology 2008:135:660-70.
  54. Omenetti A, Popov Y, Jung Y, Choi SS, Yang L, Witek RP, Schuppan D, Diehl AM. Hedgehog Pathway Activation Parallels Expansion and Contraction of Ductular and Fibrogenic Cell Population in Cholestatic Rats. Gut 2008: 57:1275-82.
  55. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, Witek RP, Alpini G, Venter J, Vandongen HM, Syn WK, Baroni GS, Benedetti A, Schuppan D, Diehl AM. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008;118:3331-3342.
  56. Rakhimova M, Esslinger B, Schulze-Krebs A, Hahn EG, Schuppan D, Dieterich W. In Vitro Differentiation of Human Monocytes into Dendritic Cells by Peptic-Tryptic Digest of Gliadin Is Independent of Genetic Predisposition and the Presence of Celiac Disease. J Clin Immunol 2009;12:29-37.
  57. Millonig G, Hegedüsch S, Becker L, Seitz HK, Schuppan D, Mueller S. Hypoxia-inducible factor 1alpha under rapid enzymatic hypoxia: Cells sense decrements of oxygen but not hypoxia per se. Free Radic Biol Med 2009;46:182-91.
  58. Garud S, Leffler D, Dennis M, Edwards-George J, Saryan D, Sheth S, Schuppan D, Jamma S, Kelly CP. Interaction between psychiatric and autoimmune disorders in coeliac disease patients in the Northeastern United States. Aliment Pharmacol Ther 2009;29:898-905.
  59. Leffler DA, Dennis M, Edwards George JB, Jamma S, Magge S, Cook EF, Schuppan D, Kelly CP. A simple validated gluten-free diet adherence survey for adults with celiac disease. Clin Gastroenterol Hepatol 2009;7:530-6.
  60. Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2009;24:564-8.
  61. Freitag T, Rietdijk S, Junker Y, Popov Y, Bhan AK, Kelly CP, Terhorst C, Schuppan D. Gluten-sensitive enteropathy can be induced by adoptive transfer of gliadin-primed CD4+ T cells: a mouse model for celiac disease. Gut 2009;58:1597-1605.
  62. Leffler DA, Dennis M, Edwards George J, Jamma S, Cook E, Schuppan D, Kelly CP. A Validated Disease Specific Symptom Index for Adults with Celiac Disease. Clin Gastroenterol Hepatol 2009;7:1328-34.
  63. Lohwasser C, Neureiter D, Popov Y, Bauer M, Schuppan D. Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol 2009; 15:5789-98.
  64. Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sägesser H, Niedobitek G, Goodman SL, Schuppan D. Pharmacological inhibition of integrin alphav beta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009;50:1501-11.
  65. Freitag T, Cham C, Sung HH, Beilhack GF, Durinovic-Belló I, Patel SD, Bronson RT, Schuppan D, Sønderstrup G. The human risk allele HLA-DRB1*0405 predisposes class II transgenic Ab0 NOD mice to autoimmune pancreatitis. Gastroenterology, in press.
  66. Popov Y, Sverdlov DY, Bhaskar KR, Sharma AK, Millonig G, Patsenker E, Krahenbuhl S, Krahenbuhl L, Schuppan D. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol, in press.

Reviews and Editorials: 2005-2009


  1. Schuppan D, Dennis MD, Kelly CP. Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management. Nutr Clin Care 2005;8:54-69.
  2. Koning F, Schuppan D, Cerf-Bensussan N, Sollid LM. Pathomechanisms in celiac disease. Best Pract Res Clin Gastroenterol 2005;19:373-87.
  3. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol 2005;43:901-10. 
  4. Mueller S, Afdhal NH, Schuppan D. Iron, HCV, and liver cancer: hard metal setting the pace? Gastroenterology 2006;130:2229-34. 
  5. Stickel F, Schuppan D. Herbal hepatotoxicity. J Hepatol 2006;45:335-6.
  6. Schuppan D, Kelly CP, Krauss N. Monitoring non-responsive patients with celiac disease. Gastrointest Endosc Clin N Am 2006;16:593-603.
  7. Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis. 2007;39:293-304.
  8. Schuppan D, Junker Y. Turning swords into plowshares: transglutaminase to detoxify gluten. Gastroenterology 2007;133:1025-8.
  9. Dieterich W, Schuppan D. Is gliadin harmful from the first morsel? Dig Liver Dis 2007;39:917-21.
  10. Schuppan D, Kelly CP. Serological screening for celiac disease. Nat Clin Pract Gastroenterol 2008;5:70-71.
  11. Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008:14:1-14.
  12. Hopfner M, Schuppan D, Scherubl H. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives. World J Gastroenterol. 2008;14:2461-73.
  13. Schuppan D, Afdhal NH. Lancet Seminars: Liver cirrhosis. Lancet 2008; 371:838-51.
  14. Hopfner M, Schuppan D, Scherubl H. Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives. World J Gastroenterol 2008;14:7021-32.
  15. Elli L, Bergamini CM, Bardella MT, Schuppan D. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis 2009;51:541-50.
  16. Schuppan D, Popov Y. Rationale and targets for treatment of liver fibrosis. Gastroenterol Clin Biol 2009;33:959-67.
  17. Popov Y, Schuppan. Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies. Hepatology 2009;50:1294-1306.
  18. Schuppan D, Junker Y, Barisani D. Celiac Disease: From Pathogenesis to novel therapies. Gastroenterology 2009;137:1912-33.
  19. Marietta E, Schuppan D, Murray JA. In vitro and in vivo models of celiac disease.Exp Opin Drug Discov, in press.
  20. Popov Y, Schuppan D. CD8+ T cells drive adipose tissue inflammation - A novel clue for NASH pathogenesis? J Hepatol, in press.

Contact Information

Detlef Schuppan, MD, PhD
Department of Medicine
Division of Gastroenterology
Beth Israel Deaconess Medical Center
330 Brookline Ave, DA-506
Boston, MA 02215
617-667-2371
617-667-2767
dschuppa@bidmc.harvard.edu

Find a Researcher

Connect With Us:
RSS
Facebook
Twitter
YouTube
Read our BIDMC
Read our BIDMC E-LettersE-Letters

© 2013 Beth Israel Deaconess Medical Center
330 Brookline Avenue, Boston, MA 02215
617-667-7000  |  TDD: 800-439-0183  | Maps & Directions